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Abstract
Although our previous GWAS failed to identify SNPs associated with pulmonary function at
the level of genomewide significance, it did show that the heritability for FEV1/FVC was
41.6% in a Japanese population, suggesting that the heritability of pulmonary function traits
can be explained by the additive effects of multiple common SNPs. In addition, our previous
study indicated that pulmonary function genes identified in previous GWASs in non-Japa-
nese populations accounted for 4.3% to 12.0% of the entire estimated heritability of FEV1/
FVC in a Japanese population. Therefore, given that many loci with individual weak effects
may contribute to asthma risk, in this study, we created a quantitative score of genetic load
based on 16 SNPs implicated in lower lung function in both Japanese and non-Japanese
populations. This genetic risk score (GRS) for lower FEV1/FVC was consistently associated
with the onset of asthma (P = 9.6 × 10−4) in 2 independent Japanese populations as well as
with the onset of COPD (P = 0.042). Clustering of asthma patients based on GRS levels
indicated that an increased GRS may be responsible for the development of a particular
phenotype of asthma characterized by early onset, atopy, and severer airflow obstruction.
Introduction
Reduced lung function at birth is a risk factor for asthma at 10 years of age [1]. Recently, genes
implicated in fetal lung development have also been reported to influence asthma susceptibility
and treatment response, supporting the involvement of deregulated lung development in the
early ontogeny of asthma [2]. Adverse factors affecting lung development during fetal life and
early childhood reduce the attainment of maximum lung function and accelerate lung function
decline in adulthood, thereby predisposing individuals to reduced lung function and increased
respiratory morbidity, particularly asthma and COPD, throughout life [3]. We have previously
reported that TSLP gene variants, as a potential susceptibility locus to asthma [4], was
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associated with lower lung function in healthy individuals, which is also in line with the con-
tention that genetic determinants of lung function influence susceptibility to asthma [5]. In
addition, several cluster analyses of asthmatic patients including ours indicated that lung func-
tion was among the important discriminating factors of the asthma phenotype [6, 7]
To date, genomewide association studies (GWASs) on pulmonary function including pre-
dicted percentage of forced expiratory volume in 1 second (%FEV1) and ratio of forced expira-
tory volume in 1 second to forced vital capacity (FEV1/FVC) have identified a number of risk
loci in multiethnic populations [8–13]. Although our previous GWAS failed to identify SNPs
associated with pulmonary function at the level of genomewide significance in a Japanese pop-
ulation, it did demonstrate that the heritability of pulmonary function can be explained by
additive effects of multiple common SNPs, providing compelling evidence for a strong genetic
influence on FEV1/FVC [14]. Furthermore, our study indicated that lung function genes identi-
fied in previous GWASs in non-Japanese populations accounted for 4.3% to 12.0% of the entire
estimated heritability of FEV1/FVC in a Japanese population. Therefore, in the current study,
we constructed a multi-SNP genetic risk score (GRS) for reduced FEV1/FVC using genotype
information for 16 genes associated with lower FEV1/FVC in a GWAS of Japanese populations
as well as in previous GWASs of non-Japanese populations. In this study, we investigated the
relationship between the onset of asthma and genetic susceptibility to lower lung function as
indicated by a multi-SNP GRS, and also attempted to identify a relevant asthma phenotype
associated with an increased multi-SNP genetic score.
Materials and Methods
Ethics Statement
This study was approved by the Human Genome Analysis and Epidemiology Research Ethics
Committee of the University of Tsukuba and by the Human Genome/Gene Analysis Research
Ethics Review Committees of the Tsukuba Medical Center, RIKEN, and the Hokkaido Univer-
sity School of Medicine. Written informed consent was obtained from each participant in
accordance with institutional requirements and the principles of the Declaration of Helsinki
(IRB approval date: January 31st, 2008; IRB number: 2008-01-31).
Study populations
We defined 3 cohorts. (1) “Tsukuba cohort”: 1364 healthy adults who visited the Tsukuba
Medical Center for an annual health checkup and 578 asthmatic patients from the Tsukuba
University Hospital and its affiliated hospitals [5, 6, 15]. For the Tsukuba cohort, we conducted
GWAS genotyping in 967 healthy adults and 244 asthmatic patients [14, 15]. (2) “Hokkaido
cohort”: 998 healthy adults and 565 asthmatic patients from the Hokkaido University Hospital
and its affiliated hospitals [15, 16]. (3) “COPD cohort”: 562 COPD patients were studied. Of
those, 307 patients were from the Hokkaido University Hospital and its affiliated hospitals
[17]; the other 255 patients were newly recruited at the University of Tsukuba and its affiliated
hospitals. The participants’ characteristics are summarized in S1 Table. The data were pre-
sented as means ± SDs unless otherwise indicated.
Diagnosis criteria for asthma and COPD
Asthma was diagnosed by respiratory physicians according to the American Thoracic Society
criteria [15]. COPD patients were enrolled when they showed chronic irreversible airflow limi-
tation defined by an FEV1/FVC< 70% after the inhalation of a β2-agonist. Patients with
COPD were carefully screened to exclude those with asthma [17]. Patients were also excluded
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if they had other significant respiratory diseases, such as lung cancer, eosinophilic pneumonia,
or pulmonary tuberculosis, on the basis of the questionnaire and chest X-ray results [5, 14, 15]
Pulmonary function data
Spirometry was required in order to meet the criteria established by the Japanese Respiratory
Society (JRS) [18]. For the 1364 healthy adults who visited the Tsukuba Medical Center for an
annual health checkup, pulmonary function was measured using an electronic spirometer
(Autospiro series; Minato Medical Science, Osaka, Japan), as described previously [14, 19].
Briefly, well-trained spirometry technicians continuously monitored the procedure and
reviewed the flow-volume curves to ensure adherence to the standards. Participants performed
up to 3 forced expiratory maneuvers so that acceptable maneuvers could be obtained. Broncho-
dilation was not applied. Annual decline of FEV1 was calculated as previously described [19].
Data for FEV1/FVC were available for all the participants, and data for annual decline of FEV1
were available for 803 nonasthmatic, non-COPD individuals [19].
Genotyping
Two hundred forty-four patients with asthma and 967 nonasthmatic, non-COPD controls
underwent GWAS genotyping [14, 15]. For those individuals without GWAS genotyping (899
asthmatic patients, 562 COPD patients, and 1395 nonasthmatic, non-COPD healthy individu-
als), genotypes for 16 SNPs were defined using the TaqMan allele-specific amplification
method (Applied Biosystems, Foster City, CA, USA), as described previously [4].
Statistical analysis
Considering the presence of allelic heterogeneity and different linkage disequilibrium patterns
according to different ethnicities, 24 genes previously associated with FEV1/FVC with proba-
bility values less than 5.0 x 10−8 (S2 Table) were tested for gene-level replications rather than
for SNP-level replications in Japanese nonasthmatic, non-COPD individuals (N = 967) in the
Tsukuba cohort [14]. We selected a top SNP with the strongest statistical evidence of associa-
tion in each region extending ± 100 kb from each candidate gene for lung function, as
described previously [14]. Because 16 of the 24 genes were nominally associated with FEV1/
FVC in the Japanese nonasthmatic, non-COPD individuals, we used the genotype information
from these 16 genes to calculate the multi-SNP genetic risk score (GRS) for lower FEV1/FVC in
each participant. The GRS, which combines the modest effects of multiple SNPs into a single
variable, is calculated as the weighted sum of the number of high-risk alleles, where the GRS
for person is
GRSi ¼
X16
k¼1
jbkjRAk
GRSi: GRS for individual i
βk: regression coefficient of SNPk as the weight of each risk allele derived from our GWAS
for FEV1/FVC
RAk: number of risk alleles for SNPk (0, 1, or 2)
The score was then divided by the highest risk score multiplied by 100 to rescale the scores
to a range between 0 and 100. We used a linear mixed model (SPSS version 22) to compare the
GRSs of healthy participants and of patients with asthma or COPD. The standardized coeffi-
cient “β” was selected as the weight (instead of, for example, simply counting the number of
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risk alleles) because it considers both the expected magnitude and direction of effect of an indi-
vidual SNP.
To estimate the dose effect of a GRS for asthma, using 1143 patients with asthma and 2362
healthy adults, we conducted a Cochran-Armitage trend test for the prevalence of asthmatic
patients according to the different ranges of the GRS using R software (version 3.1.1) [20].
To examine whether the significant association between a GRS and asthma is driven by a
single SNP, the association analysis was repeated by recalculating the GRS after excluding the
genotype information from each of the 16 SNPs (a leave-one-out sensitivity analysis).
To identify distinctive patient characteristics related to an increased GRS level, we applied
k-means cluster analysis to the asthmatic patients by including the GRS as a discriminating
variable. For this cluster analysis, among a total of 1143 asthma patients in the study, 1063
patients with complete data on GRS, age at onset, and %FEV1 were studied. Because several
cluster analyses of asthma including ours showed that age at onset of asthma and %FEV1 were
the most important discriminators for asthma [6], in addition to the GRS, age at onset of
asthma and %FEV1 were intentionally selected for this cluster analysis. Differences in demo-
graphic and clinical characteristics between the resulting clusters were analyzed using ANOVA
for continuous normally distributed variables, chi-squared tests for categorical variables, and
the Kruskal-Wallis test for non-normally distributed variables. Although our previous cluster
analysis identified 6 clusters largely based on age at onset of asthma and %FEV1 [6], in the cur-
rent study, the clustering that resulted in 5 groups was chosen for further analysis because of a
clinical judgment that going from 5 to 6 groups resulted in patient clinical characteristics
becoming more homogeneous rather than more distinct; especially, the number of clusters (k)
that gave the maximum difference in the GRS score among the k clusters was 5 (S3 Fig). Then,
given the 5 distinct clusters, we applied multinomial logistic regression analysis to examine
association of a GRS with each of the 5 asthma clusters, which was adjusted for sex, age, atopy,
smoking index group, and the cohorts.
To explore the biologic pathways related to a GRS, the Gene Relationships Among Impli-
cated Loci (GRAIL) program was applied [21]. Briefly, GRAIL is a text mining tool that identi-
fies nonrandom, evidence-based links between genes using PubMed abstracts. On the basis of
the textual relationships between genes, GRAIL assigns a probability value to each region sug-
gesting its degree of functional connectivity among genes at different loci. As input, we
uploaded 16 SNPs used for the construction of a GRS. The GRAIL algorithm is available online
at https://www.broadinstitute.org/mpg/grail/. We used the VIZ-GRAIL software (http://www.
broadinstitute.org/mpg/grail/vizgrail.html) [22], which was implemented as 2 separate perl
scripts, to visualize the results from the GRAIL analysis with default parameters. To explore
the biologic relevance of a GRS, we also conducted pathway enrichment analysis for FEV1/
FVC using MetaCore™ software (Thomson Reuters, Philadelphia, PA, USA), an integrated soft-
ware suite for functional analysis of all omics data, which connects the inputted SNPs to bio-
logic effect or function to define the biologic relevance of the SNPs to lower lung function. We
uploaded SNPs with probability values less than 0.05 in our GWAS of FEV1/FVC (n = 24,309)
for the enrichment analysis, and we then compared the results of GRAIL and MetaCore™ to
identify possible clues to the molecular events leading to asthma.
Results
Among the 24 genes associated with FEV1/FVC in 6 previous GWASs in non-Japanese popula-
tions, we found that 16 genes were nominally associated with FEV1/FVC in a Japanese non-
asthmatic, non-COPD population (S3 Table). A multi-SNP genetic risk score, or GRS,
calculated on the basis of these 16 SNPs for healthy individuals in the Tsukuba cohort follows a
Lung Function Genes and Asthma
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normal distribution (S1 Fig). The GRS for lower FEV1/FVC was significantly correlated with
FEV1/FVC in 1364 healthy individuals in the Tsukuba cohort (R
2 = 0.040, P = 4.1 × 10−14), but
not with an annual decline in FEV1 in 803 healthy individuals (R
2 = 0.0001, P = 0.34) (S2 Fig).
Compared with GRS levels in healthy individuals, we found significantly higher levels of
GRS in patients with asthma in the Tsukuba cohort (P value = 0.033) (Table 1). We replicated
this significant association between a GRS and asthma in the independent Hokkaido cohort (P
value = 0.014). GRS levels were consistently higher in patients with asthma than in those in
healthy adults; in the combined analysis of the Tsukuba and Hokkaido cohorts, higher levels of
GRS were associated with the presence of asthma with the adjusted P value of 9.6 × 10−4. These
results did not change when individuals with a smoking history of over 10 pack-years were
excluded from the analysis. In addition, GRS levels were also significantly higher in patients
with COPD (Table 1).
The Cochran-Armitage trend test showed that the prevalence of asthma increased as GRS
levels increased (P = 0.0059) (Fig 1). In contrast, the prevalence of atopic status did not change
according to GRS levels (P = 0.46), indicating that association between the GRS and presence
of asthma was independent of atopic status.
In the sensitivity analysis, we calculated a GRS based on 15 SNPs excluding each of the 16
SNPs (S4 Table). Every GRS calculated based on each of the 15 SNPs was also significantly
associated with asthma, suggesting that none of the single SNPs drives the significant associa-
tion between a GRS and asthma in the current study.
Our cluster analysis revealed 5 distinct asthmatic clusters (Fig 2). The cluster with the high-
est GRS (n = 197) was characterized by the youngest age at onset, moderate-to-severe lung
function, the highest levels of total IgE, the highest prevalence of atopy (sensitizations to com-
mon inhaled allergens), and the lowest prevalence of smokers (S5 Table). In a multinomial
logistic regression analysis, the strongest association between GRS levels and asthma was found
in this particular cluster (P = 3.6×10−5, S6 Table).
To explore the biologic relevance of a GRS, we applied the top SNPs at 16 genes to the
GRAIL program (Fig 3). For each SNP, GRAIL identified the genomic region in linkage dis-
equilibrium and identified the overlapping genes. It then checked to see how many other loci
already known to be associated with FEV1/FVC contained functionally related genes. GRAIL
determined the corresponding probability values for all gene–gene connections. The outer ring
contains the input SNPs, and the inner ring shows all possible genes corresponding to each
Table 1. Association between genetic risk score and onset of asthma or COPD.
cohort Tsukuba cohort Hokkaido cohort Combined Combined
(smoking
index ≦ 200)
COPD cohort
status HV BA HV BA HV BA HV BA HV COPD
Number 1364 578 998 565 2362 1143 1604 857 2362 562
GRS (mean) 56.06 56.79 56.09 56.96 56.07 56.87 55.97 56.73 56.07 56.53
GRSh (SD) 7.2 6.7 7.6 7.3 7.4 7.0 7.3 7.1 7.4 6.8
P value 0.037 0.014b 0.0022 0.013 0.021b
P value (corrected)a 0.033 0.007b 9.6×10−4 0.0020 -
HV, healthy volunteer; BA, bronchial asthma; COPD, chronic obstructive pulmonary disease; SD, standard deviation
aCorrected for sex, age, smoking index group, and atopy. In the combined analysis, cohort effects was also adjusted using the random effect model.
bone-sided test
doi:10.1371/journal.pone.0145832.t001
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SNP locus. GRAIL indicated the presence of possible underlying biologic networks across these
16 loci. FAM13A, one of the genes annotated by the 16 SNPs, was the most functionally con-
nected gene when that locus was scored against the 15 other validated risk loci (S7 Table).
MetaCore™ revealed several pathways associated with FEV1/FVC using the results of our
GWAS (S8 Table). Among the top 20 pathways, two, “Signal transduction calcium signaling”
and “Development regulation of epithelial-to-mesenchymal transition (EMT),” included genes
that were annotated by GRAIL based on the 16 SNPs. Specifically, the EMT pathway contained
3 genes: TGFB2, TNF, and NOTCH4.
Discussion
The GRS level for lower FEV1/FVC calculated based on the 16 SNPs was significantly higher in
patients with asthma than in healthy adults, suggesting that a genetic susceptibility to lower
lung function may predispose to asthma. Although both reduced growth and accelerated lung
function decline lead to lower lung function levels in adults, given that the GRS calculated
using 16 SNPs was not associated with annual lung function decline in the healthy participants,
we believe that these 16 SNPs (or gene pathways involving these 16 SNPs) may be involved in
the deregulated lung growth or development rather than in the accelerated decline of lung
function. In support of this contention, lung function genetic variants identified in adults
including ARMC2, FAM13A, GPR126, KCNE2, NCR3, PID1, RARB, and THSD4 were recently
Fig 1. Prevalence of asthma according to GRS levels. The X-axis shows the GRS ranges. The left Y-axis shows the number of healthy individuals and
asthmatic patients for each GRS range. The right Y-axis shows the percentages of asthmatic patients and atopic individuals for each GRS range. The upper
line shows the percentage of atopic individuals for each given GRS range. The lower line shows the percentage of asthmatic patients for each given GRS
range. Atopy was defined as the presence of specific IgE antibody toward at least 1 common inhaled allergen. HV, healthy volunteer, BA, bronchial asthma.
doi:10.1371/journal.pone.0145832.g001
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associated with the development of lung function measures such as FEF50 and PD20 during
early childhood [23].
We found that a GRS was associated with COPD as well as with asthma. The present study,
therefore, may identify a common susceptibility factor underlying asthma and COPD, stressing
the importance and implications of these genetic variants in the development of lung function
in early life and later progression to asthma and COPD [24]. Accordingly, our findings support
the Dutch hypothesis that airway obstruction associated with asthma and COPD is related to
different expressions of a primary abnormality in the airways and that both host and environ-
mental factors play a part in the pathogenesis [25]. Alternatively, our findings suggest that the
asthma–COPD overlap can have its origins in childhood [26]
The difference in the levels of GRS between healthy individuals and asthmatic patient was
rather small, which suggested that contribution of genetic susceptibility to lower lung function
to asthma is restricted to particular subphenotypes of asthma. Indeed, our clustering of asthma
patients according to GRS levels showed that the GRS was specifically related to a particular
phenotype characterized by early-onset of the disease, atopy, and severer airflow obstruction,
suggesting that deregulated lung function development ascribed to a GRS might be an impor-
tant genetic determinant specific to this particular phenotype. In the Severe Asthma Research
Program cohort, a similar cluster was identified that was characterized by early-onset atopic
asthma with advanced airflow limitation. The prevalence of this cluster was 18%, and the chil-
dren in this cluster had the highest exhaled nitric oxide values, the highest extent of health-care
use, and the highest daily doses of ICS, and most were receiving at least 3 asthma controller
medications [27]. The ‘‘Environment and Childhood Asthma” birth cohort study in Oslo also
Fig 2. Differences in GRS, age at onset, and pFEV1 among asthma clusters. The left Y-axis shows the mean GRS for each cluster. The right Y-axis
shows the mean age at onset asthma and the mean pFEV1 for each cluster. pFEV1, percent predicted forced expiratory volume in 1 second.
doi:10.1371/journal.pone.0145832.g002
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identified a similar asthma phenotype characterized by impaired lung function from birth
throughout childhood with atopic dermatitis and allergic rhinitis [28]. Our clustering allowed
greater specificity for a GRS as a genetic marker to identify this particular asthma phenotype/
endotype related to deregulated lung function as well as better understanding of the mecha-
nisms associated with the heterogeneity of severe asthma.
Our pathway analysis using GRAIL and MetaCore™ showed that molecules such as TGFB2,
TNF, and NOTCH4 that are related to the epithelial-mesenchymal transition (EMT) pathway
could be responsible for the biologic relevance of a GRS. The EMT is a process whereby
Fig 3. Graphic representation of functional connections between genes corresponding to the 16 SNPs.GRAIL found connections among genes in 16
loci. The outer circle shows the 16 SNPs used for the calculation of GRS. The internal ring represents the genes near each SNP. The literature-based
functional connectivity between these genes with lines drawn between them—the redder and thicker the line is, the stronger the connectivity is between the
genes.
doi:10.1371/journal.pone.0145832.g003
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epithelial cells gradually transform into mesenchyme-like cells losing their epithelial function-
ality and characteristics. EMT is a physiologic phenomenon involved in lung development [29]
and is also implicated in aberrant repair of the epithelium and accumulation of fibroblasts (tis-
sue remodeling) in specific chronic bronchial pathologies, such as asthma and COPD [26].
Accordingly, together with our pathway analysis, the biologic relevance of a GRS, which was
associated with both lung function and asthma or COPD, may involve the EMT process in the
lung.
There are some limitations to this study. Even though the 16 genes used to create a GRS
were selected on the basis of the previous GWASs conducted in non-Japanese populations, all
the study participants were Japanese, and therefore the analysis provides limited information
on other ethnic groups and may not reflect the overall asthma population. In addition,
although the clustering of asthma patients using a GRS gave some implication underlying the
heterogeneity of asthma, the likelihood always exists of spurious findings being generated by
chance. Thus, further replication should aim to confirm these results, particularly given that
the levels of significance in the study were not overwhelming.
In conclusion, we have identified a multi-SNP genetic marker, a GRS based on 16 SNPs,
associated with a specific asthma phenotype related to genetic susceptibility to lower lung func-
tion. By providing important insights into the pathways underlying the development of
asthma, the findings of this study may help us to understand the complexity of asthma pheno-
types and also to appropriately select patients for more targeted prevention and treatments in
the future.
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S1 Fig. Histogram of genetic risk scores (GRS) in healthy Japanese individuals. GRS in non-
asthmatic, non-COPD healthy individuals of the Tsukuba cohort (N = 1364). The solid line
indicates normal distribution.
(TIF)
S2 Fig. Correlation between genetic risk score and FEV1/FVC or annual decline in FEV1 in
healthy individuals. FEV1/FVC (a) or annual decline in FEV1 (b). Linear approximation is
shown by the fine black line (a).
(TIF)
S3 Fig. Differences in the GRS among the given asthma clusters according to the number
of clusters.When k-means cluster analysis was repeated for the number of clusters (k) 3, 4, 5,
6, or 7, the maximum difference in the GRS among the k asthma clusters was obtained for
k = 5 (ANOVA F = 4.8, P< 0.001).
(TIF)
S1 Table. Demographic characteristics of the study cohorts.
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S2 Table. Susceptibility genes to pulmonary function traits in previous 6 GWASs.
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